Menu
Contact Us
Subscribe
Menu

Medicines Law & Policy releases analysis, tools, and data to influence policy and practices to improve access to medicines.

Pandemic Accord

ML&P has been closely following the process towards the creation of a new international instrument to better prevent, prepare...

Our research

ML&P delves into complex public health issues, seeking to make the legal implications of international legislation clearer, and to...

Blog

Medicines Law & Policy periodically will post timely analysis and insight into current events related to intellectual property and...

TRIPS Flexibilities Database

The TRIPS Flexibilities Database contains instances when authorities have invoked, planned to invoke, or have been asked to invoke...

Latest Blog Posts from Medicines Law & Policy

The Pandemic Agreement is here

Ellen 't Hoen -
In December 2021, the member states of the World Health Organization decided “to draft and negotiate a WHO convention, agreement or other international instrument...

Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development

Christopher Garrison -
This is an excerpt from a longer report on AI, medicines development and the patent system. Download the full report here (or by clicking...

Expanding local production is essential for pandemic preparedness. It requires, however, transfer of technology.

Ellen 't Hoen -
Madam co-chairs, delegates,  This very week, from 7 to 9 April the 3rd World Local Production Forum is taking place in Abu Dhabi. Actions towards...

Respect for intellectual property law includes respecting the flexibilities it contains to protect the public interest: ML&P’s opening statement to the INB

Kaitlin Mara -
Thank you for the opportunity to speak. And for the latest draft of the pandemic agreementshared with us on 26 March. In particular, we...

Will Europe block the Pandemic Agreement because of one word?

Guilherme Ferrari Faviero and Ellen 't Hoen -
This commentary originally appeared in the Brussels Times, and is available here. The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...

“Mutually agreed terms and conditions,” says it all.

Ellen 't Hoen -
On 4 March, Politico reported that the Polish presidency of the Council of the European Union (EU) is expressing doubt that the Pandemic Agreement...

“This week, the medicines were not there”: What is at stake in the pandemic agreement

Ellen 't Hoen -
Earlier this week I listened to a testimony from a community worker at a maternity ward where HIV-positive women gave birth. 17 babies were...

A better way to solve a crisis: A new mechanism for incentivising R&D on new antimicrobials

Kaitlin Mara -
Antimicrobial resistance is the ‘silent’ pandemic: Globally, it costs 5 million lives a year, and is set to rise to more than 8 million...

The world needs a signal that multilateralism works: ML&P opening statement to the INB13, 17 February 2025

Ellen 't Hoen -
Thank you for the opportunity to make a brief statement. The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...

Synthesis and Conclusions: Securing technology transfer in the Pandemic Agreement

Suerie Moon -
This guest blog draws from the discussions at a 27 January 2025 expert workshop organised by the Geneva Graduate Institute entitled Technology Transfer in...
See all blogs

Bluesky

Follow the ML&P team on Bluesky:

Medicines Law & Policy
Ellen 't Hoen
Kaitlin Mara
Katrina Perehudoff

Research Highlights

Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade secrets. We drafted one.

Medicines Law & Policy

15 July 2022

Seven recommendations for sharing IP, know-how and technology – report of Global Expert Group on the Pandemic Treaty

BMJ Global Health

15 July 2022

Scaling-up Vaccine Production Capacity: Legal Challenges and Recommendations

The Independent Panel for Pandemic Preparedness and Response

May 2021

What is the ‘know-how gap’ problem and how might it impact scaling up production of Covid-19 related diagnostics, therapies and vaccines?

Medicines Law & Policy

May 2021

EU Review of Pharmaceutical Incentives: Recommendations for Change

Medicines Law & Policy

May 2021

Posts by Topic

Medicines Law & Policy

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Never miss a post! Sign up for ML&P's newsletter.

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.